Current trial results show that obese patients using Contrave are about 41% less likely to experience any major heart event (e.g. heart attack, strokes, or heart-related deaths) than those on a placebo. Specifically, the results show that Contrave leads to a 30% reduction in heart attacks, a 37% reduction in strokes, and a 74% reduction in heart-related deaths. This is early data, but very promising in our view.